CRISPR-Engineered immune cells take on tough blood cancers
NCT ID NCT06492304
First seen Apr 05, 2026 · Last updated May 20, 2026 · Updated 6 times
Summary
This study tested a new treatment called CTX131 for adults with certain blood cancers (T cell lymphoma, B cell lymphoma, or acute myeloid leukemia) that came back or didn't respond to standard therapy. CTX131 uses CRISPR gene editing to create donor immune cells that target and attack cancer cells. The trial involved 12 participants and focused on safety and how well the treatment works, with the goal of controlling the disease rather than curing it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site 1
Houston, Texas, 77030, United States
-
Research Site 2
The Bronx, New York, 10467, United States
-
Research Site 3
Boston, Massachusetts, 02114, United States
-
Research Site 4
New York, New York, 10065, United States
-
Research Site 5
Stanford, California, 94305, United States
-
Research Site 6
Phoenix, Arizona, 85054, United States
-
Research Site 7
East Melbourne, Victoria, 3002, Australia
Conditions
Explore the condition pages connected to this study.